Free tool
FAERS Monitor: Iclusig
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203469 or its brand name (Iclusig, Ponatinib Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
5,237
Serious
4,483
86% of reports
Hospitalization
1,673
Death reported
1,478
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death756
- off label use350
- rash272
- headache268
- fatigue260
- pyrexia255
- neoplasm progression197
- drug ineffective195
- hypertension195
- nausea195
- constipation192
- platelet count decreased166
- arthralgia164
- abdominal pain160
- chronic myeloid leukaemia150
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 595 |
| 2014 | 637 |
| 2015 | 357 |
| 2016 | 611 |
| 2017 | 416 |
| 2018 | 305 |
| 2019 | 337 |
| 2020 | 408 |
| 2021 | 331 |
| 2022 | 250 |
| 2023 | 275 |
| 2024 | 305 |
| 2025 | 260 |
| 2026 | 150 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,922 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic myeloid leukaemiaSignal | 150 | 134.8 | 114.9 | 19,156 |
| neoplasm progressionSignal | 197 | 22.9 | 19.9 | 4,084 |
| platelet count decreasedSignal | 166 | 6.3 | 5.4 | 732 |
| hypertensionSignal | 195 | 3.7 | 3.2 | 385 |
| constipationSignal | 192 | 3.5 | 3.1 | 350 |
| deathSignal | 756 | 3.5 | 3.3 | 1,423 |
| pyrexiaSignal | 255 | 3.0 | 2.6 | 335 |
| abdominal painSignal | 160 | 2.8 | 2.4 | 180 |
| rashSignal | 272 | 2.5 | 2.2 | 250 |
| headache | 268 | 1.7 | 1.5 | 82 |
| off label use | 350 | 1.6 | 1.5 | 83 |
| arthralgia | 164 | 1.6 | 1.4 | 35 |
| fatigue | 260 | 1.3 | 1.2 | 23 |
| nausea | 195 | 1.0 | 0.9 | 0 |
| drug ineffective | 195 | 0.6 | 0.5 | 57 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.